Latest Healthcare News

IMEXHS Limited delivered FY25 results at the top end of guidance, reporting a 10% revenue increase and a tripling of underlying EBITDA. The company’s software and radiology services both showed solid growth, setting the stage for an optimistic FY26 outlook.

Memphasys Limited has advanced its Felix™ System commercial rollout with key regulatory approvals and new international contracts, while trimming operating costs and narrowing losses in the first half of FY2026.

Elanor Investors Group reported a $24.5 million net loss for the half year to December 2024, grappling with debt covenant breaches and defaults. The group has struck a $125 million recapitalisation agreement with Rockworth Capital Partners to stabilise its balance sheet and pursue growth.

Lumos Diagnostics reported a 74% increase in its half-year loss to US$4.88 million, despite strong progress with its FebriDx diagnostic test and a landmark US distribution agreement. The company awaits a critical FDA decision that could unlock significant revenue growth.

Mach7 Technologies reported a 23% drop in revenue to $13.65 million for H1 FY26, alongside a sharp increase in net loss to $5.75 million, as it embarks on a strategic commercial reset and expands its Asia-based engineering capabilities.

4DMedical Limited’s half-year report reveals rapid commercial traction following FDA clearance of its CT:VQ™ imaging technology, alongside a $150 million institutional placement that bolsters its cash reserves for global expansion.

Careteq Limited reported a widening half-year loss with revenues down 18%, announcing plans to sell its Embedded Health Solutions business to strengthen its balance sheet and focus on its HMR Referral platform.

ReNerve Limited reported a half-year loss of $2.72 million, up 47% from last year, as it expands its nerve repair product portfolio and secures new regulatory approvals in Asia-Pacific.

Sigma Healthcare has delivered a robust first half of FY26, posting a 15% rise in revenue driven by strong domestic and international sales growth, alongside operational synergies and strategic store expansions.

Ramsay Health Care’s half-year results reveal a dramatic net profit rebound, driven by prior year impairments and solid growth in Australia and Europe. The company also announced a strategic acquisition and a proposed share distribution.

Control Bionics Limited reported a sharp increase in losses for the half-year ending December 2025, coinciding with its acquisition of full control over Neuro Elite Athletics, LLC. The company faces ongoing financial challenges despite no dividends being declared.

United Overseas Australia Ltd reported a robust 61.7% increase in net profit for the year ended 31 December 2025, alongside a 48% rise in revenue. The company declared a final unfranked dividend of 2.00 cents per share, maintaining its payout despite strong earnings growth.